Benicar is linked to severe gastrointestinal injuries. The mean duration of follow-up ranged from 1.7 to 4.8 years.The study reported the frequencies of new cancer occurrence to be 7.2% for patients receiving ARBs compared to 6.0% for those not receiving ARBs (risk ratio = 1.08, 95% Confidence Interval: 1.01-1.15). Current As of March 2019, manufacturers have not found such contamination in any lots of Benicar. At ConsumerSafety.org, Curtis managed the day-to-day publication of all content from 2016-2019.Medications That Cause Depression Could Be a Bigger Problem Than First Thought© 2020 CSO Technology Partners, LLC. While a handful of cases are still working their way through federal courts, we are no longer taking new Benicar cases.The Benicar settlement totals $358 million and covers more than 2,200 cases. Since the FDA recommended label change in 2013, the drug has been considered safe to use as long as health care providers remain vigilant about the side effects.More than 97% of outstanding Benicar lawsuits agreed to the settlement proposed by Daichii Sankyo in August 2017. FDA’s meta-analysis of 31 randomized controlled trials comparing ARBs to other treatment found no evidence of an increased risk of incident (new) cancer, cancer-related death, breast cancer, lung cancer, or prostate cancer in patients receiving ARBs.We comply with the HONcode standard for trustworthy health information - The content on this page is provided for informational purposes only. A handful of plaintiffs who rejected the settlement are still pursuing their cases in the District of New Jersey.No. The Benicar lawsuit claimed the makers of Benicar failed to warn doctors and patients that the drug could cause sprue-like enteropathy. Other similar drugs, known as sartans, have recently been the subject of numerous recalls due to carcinogenic contaminants found in test lots. The FDA Alert(s) below may be specifically about Benicar HCT or relate to a group or class of drugs which include Benicar HCT (hydrochlorothiazide/olmesartan).MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com.

Following is a list of possible medication recalls, market withdrawals, alerts and warnings. BENICAR HCT ® (olmesartan medoxomil-hydrochlorothiazide) is a combination of an angiotensin II receptor antagonist (AT 1 subtype), olmesartan medoxomil, and a thiazide diuretic, hydrochlorothiazide (HCTZ).. Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. However, not all of the plaintiffs who file a lawsuit will receive the same amount. Benicar (olmesartan medoxomil), Benicar HCT, Azor, Tribenzor, OlmetecSprue-Like Enteropathy, Serious Gastrointestinal Injuries, Villous Atrophy, Malnutrition, Colitis, Gastritis, DeathThe legal forms on this website are secure and protect the Learn about your legal options and get free evaluations from attorneys experienced with product liability and personal injury cases.Attorney Advertising. Brought to you by The Meneo Law Group, LLP. The U.S. Food and Drug Administration has not yet issued a recall for Benicar despite the fact that the drug has been linked to dangerous side-effects. For the latest FDA MedWatch alerts, Audience: Cardiology, Pharmacy, Family Practice, EndocrinologyHealthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:FDA will continue to evaluate the safety of olmesartan-containing products and will communicate again if additional information becomes available.Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:The meta-analysis included data from over 60,000 patients in several long-term, randomized, controlled clinical trials evaluating ARBs for which adverse events related to cancer were captured during the study. The site is sponsored by law firms. Other Information. We’re serious about providing trustworthy information that meets our publishing standards. The blood pressure medication Benicar (olmesartan medoxomil)—and its sister drugs Benicar HCT, Azor, and Tribenzor—have been linked to serious gastrointestinal injury, prompting thousands of lawsuits against drug maker Daiichi Sankyo. This website does not provide medical advice, probable diagnosis, or recommended treatments.Curtis Weyant has more than 20 years as a writer, editor, and communicator, publishing on a wide variety of topics, especially in the financial, legal, and medical fields. Benicar lawsuits led to a $300 million settlement. The information on ConsumerSafety.org is provided for informational purposes only and is not intended to provide specific legal advice. No statistically significant difference in cancer deaths was noted.Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:[UPDATED 04/14/2011] After reviewing the results of the ROADMAP and ORIENT trials, FDA has determined that the benefits of Benicar continue to outweigh its potential risks when used for the treatment of patients with high blood pressure according to the drug label.